Scarica l'app Stockscreener
0.3705
12.33%
-0.0521
Pre-mercato:
.37
-0.0005
-0.13%
Scisparc Ltd Borsa (SPRC) Ultime notizie
SciSparc Ltd. Reaches Favorable Lawsuit Settlement, Secures Cash Compensation and IP Rights - TipRanks
How Are Things Looking For SciSparc Ltd (NASDAQ: SPRC) For The Short Term? - Stocks Register
SciSparc Reveals Favorable Cash Settlement In Lawsuit, Shares Up - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology - The Manila Times
SciSparc Ltd. Secures Settlement Agreement in Lawsuit Against Former Directors, Retaining Key Intellectual Property Rights - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, - GlobeNewswire
Legal Victory: SciSparc Claims $411K Settlement and Complete IP Control in Strategic Court Win - StockTitan
SPRC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
SciSparc Ltd (SPRC) Shares Soar Above 1-Year High - The News Heater
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Behind SciSparc Ltd’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Game-Changing Addiction Treatment Patent: SciSparc-Clearmind's MDMA Breakthrough Expands Global Reach - StockTitan
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
Jeffs' Brands Negotiates $11.8M Sale of Smart Repair Pro to Canadian Company in Major Restructuring - StockTitan
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
SciSparc gets Nasdaq extension to regain compliance - MSN
SciSparc (NASDAQ:SPRC) Stock Quotes, Forecast and News Summary - Benzinga
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - GlobeNewswire
SciSparc Ltd. Delivers Treatment for Autism Spectrum Disorder Clinical Trial Enabling Commencement of Dosing - Marketscreener.com
SciSparc, Automax enters direct import market with $13M first shipment of JAC EVs - MSN
SPRCSciSparc Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
SciSparc Granted Nasdaq Compliance Extension - TipRanks
SciSparc Secures Critical Nasdaq Extension to Meet $1 Minimum Bid Requirement - StockTitan
SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles - GlobeNewswire
SciSparc's AutoMax Secures First $13M JAC Motors EV Shipment for Israeli Market Launch - StockTitan
SciSparc says MitoCareX expands research to pancreatic cancer - Yahoo Finance
SciSparc Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 - Marketscreener.com
Scisparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment - Marketscreener.com
SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results - GlobeNewswire
SciSparc's MitoCareX Breakthrough: AI-Powered Platform Shows Promise in Pancreatic Cancer Treatment - StockTitan
SciSparc and Clearmind Medicine Advance with European Patent Application for Psychedelic Binge Behavior Treatment - TipRanks
Nasdaq Surges Over 200 Points; BioLineRx Shares Plummet - Benzinga
Why Is Psychedelic-SciSparc Stock Trading Higher On Monday? - AOL
Stock market today: AEON Biopharma saw gain of 255.62% while SciSparc increased by 89.77% in early trading - Business Upturn
SciSparc-Clearmind Medicine Collaboration Announces the - GlobeNewswire
SciSparc and Clearmind Secure European Patent for Groundbreaking Binge Behavior Treatment - StockTitan
Pharma Stock SciSparc Ltd. (Nasdaq: SPRC) Soars on Psychedelic News - Investorideas.com newswire
IMCA renews SciSparc’s autism spectrum disorder therapy trial approval - Yahoo Finance
SciSparc Secures Approval Renewal for Autism Treatment Trial - TipRanks
SciSparc announces renewal of approval by Israeli Medical Cannabis Agency - TipRanks
SciSparc Announces Renewal of Approval by Israeli Medical - GlobeNewswire
SciSparc Advances Autism Treatment Trial: CBD-Based SCI-210 Gets Key Israeli Approval for Children's Study - StockTitan
Scisparc Ltd. Announces Initiation of Patient Recruitment for Its Clinical Trial with Sci-210 in Children with Autism Spectrum Disorder - Marketscreener.com
SciSparc: AutoMax announces $13M first delivery of JAC vehicles - Yahoo Finance
SciSparc Supports AutoMax’s $13 Million JAC Motors Vehicle Import - TipRanks
S&P 500 Edges Lower, SciSparc Shares SurgeSEALSQ (NASDAQ:LAES), Baosheng Media Gr (NASDAQ:BAOS) - Benzinga
Stock market today: Millennium Group International surged by 318.96% while SciSparc increased by 153.01% in early trading - Business Upturn
SciSparc Shares Skyrocket With AutoMax's First JAC Motors Shipment - Yahoo Finance
SciSparc: AutoMax Announces $13 Million First Delivery of - GlobeNewswire
SciSparc's AutoMax Receives First $13M JAC Motors Shipment Following Israel Import Approval - StockTitan
SciSparc Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024 - Marketscreener.com
Scisparc Ltd. with Clearmind Medicine Inc. Publishes for the Innovative Combination of 3,4-Methylenedioxymethamphetamine with N-Acylethanolamines - Marketscreener.com
0.53%
0.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):